24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To evaluate efficacy and toxicity of stereotactic body radiation therapy (SBRT) with CyberKnife® (Accuray, Sunnyvale, CA, USA) in a selected cohort of primary, medically inoperable early-stage non-small cell lung cancer (NSCLC) patients.

          Related collections

          Author and article information

          Journal
          Strahlenther Onkol
          Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
          Springer Nature
          1439-099X
          0179-7158
          Feb 2018
          : 194
          : 2
          Affiliations
          [1 ] Department of Radiation Oncology, Center for Integrated Oncology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
          [2 ] Department of Radiation Oncology, Center for Integrated Oncology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. martin.kocher@uk-koeln.de.
          [3 ] Lung Clinic Merheim, Hospital of Cologne, Cologne, Germany.
          [4 ] Bethanien Hospital, Institute of Pneumology, University of Cologne, Solingen, Germany.
          [5 ] Department of Diagnostic and Interventional Radiology, Center for Integrated Oncology, University of Cologne, Cologne, Germany.
          [6 ] Department III of Internal Medicine, Heart Centre of the University of Cologne, Cologne, Germany.
          [7 ] Department of Cardiothoracic Surgery, Center for Integrated Oncology, University of Cologne, Cologne, Germany.
          [8 ] First Department of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
          Article
          10.1007/s00066-017-1194-x
          10.1007/s00066-017-1194-x
          28812120
          fc7ad858-7f6d-4741-ab6f-5970e2fbcde0
          History

          Radiosurgery,Fiducial markers,Adverse effects,Toxicity,Survival

          Comments

          Comment on this article